natgillin/translations-raw huggingface dataset:
myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
miokloničkih napadaja (kratki, iznenadni trzaj mišića ili skupine mišića) u odraslih i adolescenata starijih od navršene 12. godine života s juvenilnom miokloničkom epilepsijom primarno generaliziranih toničko-kloničkih napadaja (veliki napadaji, uključujući gubitak svijesti) u odraslih i adolescenata od navršene 12. godine života s idiopatskom generaliziranom epilepsijom (oblik epilepsije za koji se smatra da je genetski uvjetovan).
myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
miokloničkih napadaja (kratki, iznenadni trzaji mišića ili skupine mišića) u odraslih i adolescenata starijih od 12. godine života s juvenilnom miokloničkom epilepsijom primarno generaliziranih toničko-kloničkih napadaja (veliki napadaji, dovode do gubitka svijesti) u odraslih i adolescenata starijih od 12. godine života s idiopatskom generaliziranom epilepsijom (oblik epilepsije za koju se smatra da je genetski uvjetovana).
myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
miokloničkih napadaja (kratki, nevoljni grčevi jednog ili grupe mišića) u odraslih i adolescenata starijih od 12. godine života s juvenilnom miokloničkom epilepsijom primarno generaliziranih toničko-kloničkih napadaja (veliki napadaji, uključujući gubitak svijesti) u odraslih i adolescenata starijih od 12. godine života s idiopatskom generaliziranom epilepsijom (oblik epilepsije za koju se pretpostavlja da je genetski uzrokovana).
myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy; primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
miokloničkih napadaja (kratki, iznenadni trzaji mišića ili skupine mišića) u odraslih i adolescenata starijih od 12. godine života s juvenilnom miokloničkom epilepsijom primarno generaliziranih toničko-kloničkih napadaja (veliki napadaji, uključujući gubitak svijesti) u odraslih i adolescenata starijih od 12. godine života s idiopatskom generaliziranom epilepsijom (oblik epilepsije za koji se smatra da je genetski uvjetovan).
myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy; primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
miokloničkih napadaja (kratkih, šoku nalik trzanja mišića ili skupine mišića) u odraslih i adolescenata starijih od 12 godina života s juvenilnom miokloničnom epilepsijom; primarno generaliziranih toničko-kloničkih napadaja (velikih napadaja, uključujući gubitak svijesti) u odraslih i adolescenata starijih od 12 godina života s idiopatskom generaliziranom epilepsijom (vrsta epilepsije za koju se misli da je genetski uzrokovana).
Myopathy
miopatija
myopathy (aching muscles, muscle tenderness of weakness, not caused by exercise) kidney pain
miopatija (bolni mišići, osjetljivost na dodir i slabost mišića, što nije prouzročeno vježbanjem) bubrežni bolovi
Myopathy**
Miopatija
Myopathy, back pain, musculoskeletal pain, myalgia
miopatija, bol u leđima, bol u mišićima i kostima, mialgija
myopathy, including
FPV/RTV)
Myopathy/myositis, arthralgia, myalgia, pain in the extremities, back pain, muscle spasm, neck pain, flank pain
Miopatija/miozitis, artralgija, mijalgija, bol u udovima, bol u leđima, spazam mišića, bol u vratu, bol u boku
Myopia,
gledanju,
Myopia, Asthenopia,
arteriosklerotska
Myositis
miozitis
myositis (myalgia, myopathy, polymyalgia rheumatica and rhabdomyolysis)
miozitis (mialgija, miopatija, reumatska polimialgija i rabdomioliza)
Myositis, blood creatine phosphokinase increased
Miozitis, porast kreatinin fosfokinaze u krvi
Myositis, increased myoglobin, muscular weakness, muscle pain, arthralgia, serum lactate dehydrogenase (LDH) increased
Miozitis, povišen mioglobin, slabost mišića, bol u mišićima, artralgija, povišena razina laktat dehidrogenaze u serumu (LDH)
myositis, rhabdomyolysis, increased CPK, osteonecrosis (see section 4.4), periarthritis.
miozitis, rabdomioliza, povišene vrijednosti kreatin fosfokinaze, osteonekroza (vidjeti dio 4.4), periartritis
Myositis, rhabdomyolysis, myalgia, myopathy/CPK increased
Miozitis, rabdomioliza, mialgija, miopatija/povišenje CK
myositisp, musculoskeletal painq, pain in extremity, arthritisr
miozitisp, mišićno-koštana bolq, bol u ekstremitetima, artritisr
Myozyme contains an artificial enzyme called alglucosidase alfa – this can replace the natural enzyme which is lacking in Pompe disease.
Myozyme sadrži umjetni enzim koji se naziva alglukozidaza alfa - on može nadomjestiti prirodni enzim koji nedostaje bolesnicima s Pompeovom bolešću.
Myozyme is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid -glucosidase deficiency).
Myozyme je indiciran za dugotrajno enzimsko nadomjesno liječenje u bolesnika s potvrđenom dijagnozom Pompeove bolesti (nedostatka kisele α-glukozidaze).
Myozyme should be administered as an intravenous infusion.
Myozyme se mora primjenjivati intravenskom infuzijom.
Mysimba 8 mg/90 mg prolonged-release tablets
Mysimba 8 mg/90 mg tablete s produljenim oslobađanjem
Mysimba 8 mg/90 mg prolonged-release tablets naltrexone hydrochloride / bupropion hydrochloride
Mysimba 8 mg / 90 mg tablete s produljenim oslobađanjem naltreksonklorid / bupropionklorid
Mysimba contains 2 active substances: naltrexone hydrochloride and bupropion hydrochloride and is used in obese or overweight adults to manage weight together with a reduced calorie diet and physical exercise.
Mysimba sadrži 2 djelatne tvari: naltreksonklorid i bupropionklorid i koristi se u odraslih osoba koje su pretile ili prekomjerne težine za kontrolu njihove težine zajedno uz dijetu sa smanjenim unosom kalorija i fizičko vježbanje.
Mysimba contains lactose (a type of sugar)
Mysimba sadrži laktozu (vrsta šećera)
Mysimba has been shown to cause fits (seizures) in up to 1 in 1,000 patients (see also section 4).
Pokazalo se da Mysimba uzrokuje napadaje u do 1 na 1000 bolesnika (vidjeti također dio 4).
Mysimba is approved for use in patients with an initial body mass index of 30 or greater; it can also be given to those with a body mass index between 27 and 30 if they have additional weight-related conditions such as controlled high blood pressure (hypertension), type 2 diabetes or high levels of lipid (fat) in the blood.
Mysimba je odobrena za uporabu u bolesnika s početnim indeksom tjelesne mase od 30 ili veće; također se može dati onima s indeksom tjelesne mase između 27 i 30, ako imaju dodatna stanja povezana s težinom, kao što su kontrolirani povišeni krvni tlak (hipertenzija), dijabetes tipa 2 ili visoke razine lipida (masnoće) u krvi.
Mysimba is available in packs containing 112 tablets.
Mysimba je dostupna u pakiranju koje sadrži 112 tableta.
Mysimba is not recommended if you are over 75 years.
Mysimba se ne preporučuje ako ste stariji od 75 godina.
Mysimba may be discontinued by your doctor after 16 weeks if you have not lost at least 5 percent of your initial body weight.
Mysimba se može obustaviti od strane liječnika nakon 16 tjedana, ako niste izgubili barem 5 posto svoje početne tjelesne težine.
Mysimba might make you feel dizzy which may weaken your ability to concentrate and react.
Mysimba Vam može uzrokovati omaglicu što slabi Vašu sposobnost koncentracije i reagiranja.
Mysimba must not be used in certain patients at particular risk of side effects, including patients with severely reduced kidney or liver function, those with high blood pressure that is not under control, those who have ever had seizures (fits), certain psychological problems or who have a brain tumour or are undergoing withdrawal from alcohol or certain drugs.
Mysimba se ne smije koristiti u određenih bolesnika koji su izloženi posebnom riziku od nuspojava, uključujući bolesnike s ozbiljno smanjenom funkcijom bubrega ili jetre, onih s visokim krvnim tlakom koji nije kontroliran, osoba koje su bilo kada imale napadaje, određene psihološke probleme ili koje su imale tumor na mozgu ili prolaze odvikavanje od alkohola ili određenih droga.
Mysimba prolonged-release tablets are blue, biconvex, round tablets debossed with “NB-890” on one side.
Mysimba tablete s produljenim oslobađanjem su plave, bikonveksne, okrugle tablete s utisnutim “NB- 890” na jednoj strani.
Mysimba should not be used during pregnancy, or while breast-feeding.
Mysimba se ne smije koristiti tijekom trudnoće ili dojenja.
Mysimba with alcohol
Mysimba s alkoholom
Mysimba™ 8 mg/90 mg prolonged-release tablets naltrexone hydrochloride / bupropion hydrochloride
Mysimba™ 8 mg / 90 mg tablete s produljenim oslobađanjem naltreksonklorid / bupropionklorid
N $ (cases/controls)
N $ (slučajevi/kontrole)
n (% of patients)
n (% bolesnika)
n (%/yr)a
n (%/god)a
N (events/patients) (%)
N (događaji/bolesnice) (%)
n (ITT population)
n (ITT populacija)
N 10,200
N 11 798
N 11,798
N 11 799
N 11,799
IPB
N = 106
N = 146
N = 128†
N = 129
N = 131†
N = 128
N = 146
(N = 252)
N = 162 N = 163 p-value(a)
N = 162 N = 163 p-vrijednost(a)
n = 164
n= 164
n = 166
n= 166
N = 187
N=187
N = 188
N=188
N = 2,582
N=2582
N = 2,585
N=2585
N = 2,586
N=2586
N = 229
N = 146
N = 244
N = 106
N = 249
a N = 249
n = 249
n=249
N = 251
N=251
N = 256
N=256
N = 256
N=282
n = 259
1358
N = 282
N=251
N = 286 n (%)
+ sofosbuvir N = 286 n (%)
N = 32
N=32
N = 328
N=328
N = 330
N=330
n = 4 for genotype 2 and n = 2 for genotype 4 n = 4 for genotype 2, n = 2 for genotype 4 and n = 1 for genotype 6.
n = 4 za genotip 2 i n = 2 za genotip 4 n = 4 za genotip 2, n = 2 za genotip 4 i n = 1 za genotip 6.
n = 4 for genotype 2 and n = 4 for genotype 4
n = 4 za genotip 2 i n = 4 za genotip 4
N = 411
(N = 847)
N = 426
+OBT N = 426
N = 436
N = 411
N = 509 n (%)
Levotiroksi
N = 51
(32,9; 61,5)
N = 770 n (%)
(0,73-1,27)
N = 84
Odgovora, n (%)
n = 96 n = 90 wk 12 wk 24a
n = 96 n = 90 tj.
N = number of patients
N = broj bolesnika
N = number of subjects
N = broj ispitanika
N = number of subjects included in each group (1) TVC naïve: includes all vaccinated subjects (who received at least one dose of vaccine) who had normal cytology, were HPV DNA negative for 14 oncogenic HPV types and seronegative for HPV-16 and HPV-18 at baseline.
N = broj ispitanika uključenih u svaku skupinu (1) TVC neizloženi: uključuje sve cijepljene ispitanike (koji su primili bar jednu dozu cjepiva) koji imaju normalnu citologiju, gdje je HPV DNA negativan za 14 onkogenih tipova HPV- a i seronegativan za HPV-16 i HPV-18 na početku ispitivanja.
N = number of subjects included in each group n = number of cases (1) ATP: includes women who received 3 doses of vaccine, were DNA negative and seronegative at month 0 and DNA negative at month 6 to the relevant HPV type (HPV- 16 or HPV-18) (2) mean follow-up of 40 months post dose 3
N = broj ispitanika uključenih u pojedinu skupinu n = broj slučajeva (1) ATP: uključuje žene koje su primile 3 doze cjepiva, bile DNA negativne i seronegativne u nultom mjesecu i DNA negativne u 6. mjesecu na relevantne HPV tipove (HPV-16 ili HPV-18) (2) prosječni period praćenja od 40 mjeseci nakon 3. doze
N = number of subjects included in each group n = number of cases (1) ATP: includes women who received 3 doses of vaccine, were DNA negative and seronegative at month 0 and DNA negative at month 6 to the relevant HPV type (HPV-16 or HPV-18) (2) including 4 cases of CIN2+ and 2 cases of CIN3+ in which another oncogenic HPV type was identified in the lesion, concomitantly with HPV-16 or HPV-18.
N = broj ispitanika uključenih u pojedinu skupinu n = broj slučajeva (1) ATP: uključuje žene koje su primile 3 doze cjepiva, bile DNA negativne i seronegativne u nultom mjesecu i DNA negativne u 6. mjesecu na relevantne HPV tipove (HPV-16 ili HPV-18) (2) uključujući 4 slučaja CIN2+ i 2 slučaja CIN3+ u kojemu je drugi onkogeni HPV tip identificiran u leziji, zajedno sa HPV-16 ili HPV-18.
N = number of subjects included in each group n = number of cases (1) TVC: includes all vaccinated subjects (who received at least one dose of vaccine) irrespective of
N = broj ispitanika uključenih u pojedinu skupinu n = broj slučajeva (1) TVC: uključuje sve cijepljene ispitanike (koji su primili bar jednu dozu cjepiva) neovisno o HPV
N = number of subjects included in each group n = number of cases (1) TVC: includes all vaccinated subjects (who received at least one dose of vaccine) irrespective of HPV DNA status, cytology and serostatus at baseline.
N = broj ispitanika uključenih u pojedinu skupinu n = broj slučajeva (1) TVC: uključuje sve cijepljene ispitanike (koji su primili bar jednu dozu cjepiva) neovisno o početnom HPV DNA statusu, citologiji i serostatusu.
N = Number of subjects randomised
N = Broj randomiziranih ispitanika
n = number of subjects with SVR12 response; N = total number of subjects per group.
n = broj ispitanika s odgovorom SVR12; N = ukupni broj ispitanika u skupini
n = number of subjects with SVR12 response; N = total number of subjects per group.
n = broj ispitanika s odgovorom SVR12; N = ukupni broj ispitanika u skupini.
n = number of subjects with the event; N = total number of subjects a Per embryo transfer.
n = broj ispitanica s događajem; N = ukupni broj ispitanica a po embriotransferu.
n = randomised patients who received at least 1 dose of study medication
n = randomizirani bolesnici koji su primili najmanje 1 dozu ispitivanog lijeka
n = total number of patients per treatment group.
n = ukupni broj pacijenata po terapijskoj skupini.
n =12
n = 12
n =13
n = 13
N =207*
N=421
N =421*
N=207
N completed
Br. završenih
N Engl J Med 1987 Oct 22;317(17):1098 (letter) section 4.5), a caspofungin dose of 70-mg/m2 daily (not to exceed an actual daily dose of 70 mg) should be considered.
N Engl J Med 1987 Oct 22;317(17):1098 (letter) istodobno s određenim induktorima metaboličkih enzima (vidjeti dio 4.5).
N entered
Br. uključenih
N events/patients (%)
N događaji/bolesnice (%)
N in conversion
Br. prijelaznih
n insulin monotherapy at baseline; 50% were on 1 or 2 oral glucose-lowering medicinal product(s) in addition to insulin: Of this latter group, 80% were on metformin alone, 12% were on metformin plus sulphonylurea therapy, and the rest were on other oral glucose-lowering medicinal products.
2 Pedeset posto ispitanika je na početku liječenja primalo inzulin; 50% ih je uz inzulin je primalo 1 ili 2 oralna lijeka za snižavanje razine glukoze: u potonjoj je skupini 80% ispitanika primalo samo metformin, 12% metformin i sulfonilureju, a ostali su primali druge oralne lijekove za snižavanje razine glukoze.
N is number of subjects per model estimate. p-values for lurasidone vs. placebo were adjusted for multiple comparisons.
N je broj ispitanika za procjenu modela. p-vrijednosti za lurasidon naspram placebo bile su prilagođene za višestruke usporedbe.
N is the number of randomized subjects with at least one dose of double-blind medicine during short-term double-blind treatment. n = number of subjects with non-missing baseline and a Week 24 value.
N = broj randomiziranih ispitanika koji su primili najmanje jednu dozu dvostruko slijepog lijeka tijekom kratkotrajnog razdoblja dvostruko slijepog liječenja. n = broj ispitanika za koje nisu nedostajali podaci na početku ispitivanja i za koje je postojala vrijednost u 24. tjednu.
n median (range)
medijan (raspon)
N Number of patients evaluable for quality of life analyses
N Broj bolesnika pogodnih za analizu kvalitete života
N number of subjects per group n/% number/percentage of subjects reporting a first episode of B-CAP anytime from 2 weeks after the administration of the 3rd dose
N broj ispitanika po skupini n/% broj/postotak ispitanika koji su prijavili prvu epizodu B-CAP u bilo kojem trenutku nakon isteka 2 tjedna od primjene 3. doze
n of subjects
Broj ispitanika
N pregnancies
Broj trudnoća
N randomised
Br. randomiziranih
n reflects randomised and treated patients
a n je broj randomiziranih bolesnika
n reflects randomised and treated patients
n predstavlja randomizirane i liječene bolesnike
n the date of the first insulin up-titratio east one dose of double-blind study m
ijekom kratkoročnog dvostruko slijep m ispitivanju
N total
Ukupan broj korisnica
n, sudden death (see section 4.4)11
iznenadna smrt (vidjeti dio 4.4)11
n- olaparib
n-olaparib
n- placebo
n-placebo
N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoly-sn-glycero-3-phosphoethanolam ine (MPEG-2000-DSPE); Sucrose octasulphate; 2- [4- (2-Hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES buffer); sodium chloride and water for injections.
N-karbonil-metoksipolietilenglikol-2000)-1,2-distearoil-sn-glicero-3-fosfoetanolamin (MPEG-2000-DSPE); saharozaoktasulfat; 2- [4- (2-Hidroksietil)piperazin-1-il]etansulfonatna kiselina (HEPES pufer); natrijev klorid i voda za injekcije.
N-0409 Oslo
Θέση Τρύπιο Λιθάρι
N-2409 Elverum Norway
N-2409 Elverum Norveška
N-acetyl-l cysteine
N-acetil-L cistein
N-acetylgalactosamine 4-sulfatase, which breaks down specific substances (glycosaminoglycans) in the body.
N-acetilgalaktozamin 4-sulfataza koji razgrađuje određene tvari (glukozaminoglikane) u tijelu.
N-acetylgalactosamine.
N-acetilgalaktozamina.
N-dealkylation of the pyrrolidine nitrogen.
N-dealkilacija pirolidinskog dušika.
N-dealkylbuprenorphine is a -opioid agonist with weak intrinsic activity.
N-dealkilbuprenorfin je µ-opioidni agonist sa slabom intrinzičkom aktivnošću.
N-demethylation, catalysed by CYP1A1, CYP3A4, CYP2C8 and CYP2J2 is the major biotransformation pathway of riociguat leading to its major circulating active metabolite M-1 (pharmacological activity: 1/10th to 1/3rd of riociguat) which is further metabolised to the pharmacologically inactive N-glucuronide.
N-demetilacija, koju kataliziraju CYP1A1, CYP3A4, CYP2C8 i CYP2J2, glavni je put biotransformacije riocigvata kojim nastaje njegov glavni aktivni metabolit u cirkulaciji, M-1 (farmakološka aktivnost: 1/10 do 1/3 od riocigvata), koji se dalje metabolizira do farmakološki neaktivnog N-glukuronida.
N-depyridomethylation with and without the 3’–hydroxylation.
3’-hidroksilacijom ili bez nje.
N-desmethyl enzalutamide was not metabolized by CYPs in vitro.
N-desmetil enzalutamid nije bio metaboliziran enzimima CYP in vitro.
N-desmethyl-vandetanib is primarily produced by CYP3A4, and vandetanib-N-oxide by flavin-containing monooxygenase enzymes (FM01 and FMO3).
N-dezmetil-vandetanib proizvodi prvenstveno CYP3A4, a vandetanib-N-oksid enzimi monooksigenaze koji sadrže flavin (FM01 i FMO3).
N-hydroxyriluzole following repeated oral administration twice daily for 8 days in 16 healthy Japanese and 16 Caucasian adult males showed in the Japanese group a lower exposure of riluzole (Cmax 0.85 [90% CI 0.68-1.08] and AUC inf.
16 zdravih odraslih Japanaca i 16 zdravih odraslih muškaraca bijelaca pokazalo je manju izloženost riluzolu u skupini s japanskim ispitanicima (Cmax 0,85 [90% CI 0,68-1,08] i AUCinf.
N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose.
N- metilirani derivat pregabalina, glavni metabolit pregabalina ustanovljen u mokraći, činio je 0,9% doze.
N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose.
N-metilirani derivat pregabalina, glavni metabolit pregabalina ustanovljen u mokraći, činio je 0,9 % doze.
N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose.
N-metilirani derivat pregabalina, glavni metabolit pregabalina ustanovljen u mokraći, činio je 0,9% doze.
N-octyl-2-pyrrolidone N-methylpyrrolidone
N-oktil-2-pirolidon N-metilpirolidon
N. meningitidis bacterium: A, C, W135 and Y. These have been purified and then ‘conjugated’ (attached) to a protein carrier called tetanus toxoid (a weakened toxin of tetanus which does not cause disease, also used in tetanus vaccine), because this improves the immune response to the vaccine.
N. meningitidis: A, C, W135 i Y. Pročišćeni su, a potom „konjugirani” (povezani) na proteinski nosač pod nazivom tetanusni toksoid (oslabljeni toksin tetanusa koji ne uzrokuje bolest, također se koristi za cjepivo protiv tetanusa) jer se na taj način poboljšava imunosni odgovor na cjepivo.
n.a.
13,0
n.a. = not available
n.d. = nije dostupno
n.a. n.a.
n.p. n.p.
N.E.
NP
N.V. Organon Kloosterstraat 6 NL- 5349 AB Oss The Netherlands
N.V. Organon Kloosterstraat 6 NL- 5349 AB Oss Nizozemska
N.V. Organon Kloosterstraat 6 NL-5349 AB Oss The Netherlands
N.V. Organon Kloosterstraat 6 NL-5349 AB Oss Nizozemska
N.V. Organon Veersemeer 4 5347 JN Oss The Netherlands
N.V. Organon Veersemeer 4 5347 JN Oss Nizozemska
N/A
N/Pc
N/A
NA
N/A
pakovanja
N/A (Dogs)
EU/2/10/111/002
N/A (Dogs)
EU/2/10/111/003
N/A (Dogs)
EU/2/10/111/004
N/A (Dogs)
EU/2/10/111/006
n/a 0.0072
n/p 0,0072
N/A = “Not applicable”, there were no responders in the placebo arm, therefore, duration is not applicable
N/P = “Nije primjenjivo”, nije bilo ispitanika s odgovorom u placebo skupini, stoga trajanje nije primjenjivo
N/A = “Not applicable”, there were no responders therefore 95% CI is not applicable
N/P = “Nije primjenjivo”, nije bilo ispitanika s odgovorom stoga 95%-tni CI nije primjenjiv
N/A N/A
55,1 (42,6; 67,1)
N/A: Not Applicable
N/P: Nije primjenjivo
N/Aa
100
N/Ac
N/D
N/Ac 31.5 (28.9,
31,5 (28,9; 48,0)
N/Ac N/R
N/D
n/ad
n/pd
n/e
(81;144)
n/e
imptoma
n/e
n/p
n/N
NS3
N/R
N/Pc
N/R
N=64
N: number of patients enrolled
N: broj bolesnika uključenih u ispitivanje
n: response-evaluable patients
n: bolesnici procjenjivi na odgovor
n: response-evaluable patients
n: bolesnici u kojih se može procijeniti odgovor
n= 101
n=101
n= 13
n=13
n= 190
n=190
N= 238
N=238
n= 30
n=30
N= 32
N=32
n= 33
n=33
N= 330
N=330
N= 333
N=333
n= 58
n=58
n= 59
n=59
n= 96
n=96
n= number of cases (1) ATP: includes women who received 3 doses of vaccine, were DNA negative at month 0 and at month 6 to the relevant HPV type.
n= broj slučajeva (1) ATP: uključuje žene koje su primile 3 doze cjepiva, bile DNA negativne u nultom mjesecu i 6. mjesecu na relevantne HPV tipove.
n= number of cases (1) ATP: includes women who received 3 doses of vaccine, were DNA negative at month 0 and at month 6 to the relevant HPV type.
n= broj slučajeva (1) ATP: uključuje žene koje su primile 3 doze cjepiva, bile DNA negativne u nultom mjesecu i 6. mjesecu na relevantne tipove HPV-a.
N= Number of individuals randomized to the respective vaccination group who received at least one injection. n= Number of individuals contributing to the analysis.
N=broj osoba randomiziranih u skupinu koje su primile najmanje jednu injekciju cjepiva. n=broj osoba uključenih u analizu.
N= Number of individuals randomized to the respective vaccination group who received at least one injection. n= Number of individuals contributing to the analysis.
N=broj osoba randomiziranih u tu skupinu koje su primile najmanje jednu injekciju cjepiva. n=broj osoba uključenih u analizu.